Screener
Immunovant, Inc. IMVT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $902,110 | $713,971 |
| Accounts receivable | 1,133 | 2,084 |
| Prepaid expenses and other current assets | 42,763 | 51,180 |
| Income tax receivable | 2,813 | 427 |
| Total current assets | 948,819 | 767,662 |
| Operating lease right-of-use assets | 72 | 98 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s cash & equivalents?
- Immunovant, Inc. (IMVT) reported cash & equivalents of $902.11M in Q1 2026.
- How has Immunovant, Inc.'s cash & equivalents changed year-over-year?
- Immunovant, Inc.'s cash & equivalents increased by 26.4% year-over-year, from $713.97M to $902.11M.
- What is the long-term trend for Immunovant, Inc.'s cash & equivalents?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s cash & equivalents has grown at a 17.7% compound annual growth rate (CAGR), from $400.15M to $902.11M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Immunovant, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude